LDX's Principal Activity is the development, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-|
|vs ASX 200 (1yr)||-36.66%|
|ASX Rank||892 of 2,316|
|Sector Rank||71 of 204|
Lumos Diagnostics Holdings Limited (LDX) is a developer and manufacturer of POC diagnostic tests. The company specializes in rapid, cost-effective and point-of-care (POC) diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions and offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|Ms Catherine Robson||Non-Executive Director||Dec 2020||
Ms Catherine Robson
Ms Robson has more than 20 years' experience in management, finance and investment. Having commenced her career at Macquarie Bank, Catherine held senior roles at NAB before founding financial services business Affinity Private. Catherine is a non-executive director of ASX-listed EQT Holdings Limited, where she is the Chair of the risk committee and a member of the audit, remuneration and strategy committees. She is also a non-executive Director of Greater Bank and SCALE Investors and chairs education technology innovator TalkiPlay. Catherine is a member of WEHI's Advocacy & Support Committee and Cancer Council Victoria's Investment Committee. She is also Chair of the Risk Committee of LDX.
|Ms Lawrence Mehren||Non-Executive Deputy Chairman,Non-Executive Director||Dec 2020||
Ms Lawrence Mehren
Non-Executive Deputy Chairman,Non-Executive Director
Mr Mehren has over 20 years' experience working in the diagnostics industry, in both operational and financial roles. Between 2007 and 2012 Lawrence served as CFO and then COO of Ventana Medical Systems, a global supplier of cancer diagnostics systems which was acquired by Roche in 2008. In 2012 Lawrence assisted in the re-launch of Accelerate Diagnostics, a company dedicated to modernizing disease diagnostics, which went public on NASDAQ in 2012. Lawrence served as President, CEO and Director of the company from 2012 to January 2020. He is also member of the Risk Committee of LDX.
|Ms Bronwyn Joyce Le Grice||Non-Executive Director||Nov 2020||
Ms Bronwyn Joyce Le Grice
Ms Le Grice has 20 years' experience in the technology and health technology sectors focused on commercialization, company growth, corporate development, investment and advocacy. Bronwyn previously served as a non-executive director for ASX listed Imagion BioSystems. Bronwyn is the founder and managing director of ANDHealth, an Australian dedicated digital health commercialisation organisation. Prior to founding ANDHealth, Bronwyn served as an Investment Director and Special Advisor for Bioscience Managers Pty Ltd, a healthcare fund manager and as Head of Commercial Development and Corporate Affairs for Adherium Ltd, including as project leader for their IPO in 2015. She is also member of the Risk Committee of LDX.
|Mr Robert Sambursky||Chief Executive Officer,Executive Director||May 2019||
Mr Robert Sambursky
Chief Executive Officer,Executive Director
Mr Sambursky has over 25 years' commercial and medical industry experience in both ophthalmology and infectious disease market segments. Rob co-founded RPS, in 2004, a biotechnology company strategically focused on designing, developing, manufacturing, and marketing novel point-of-care tests for infectious diseases (which merged with Lumos in 2019). With Rob as President and CEO of RPS, the company developed multiple POC diagnostic tests which obtained international regulatory clearances, including U.S. FDA 510(k) clearances with clinical laboratory improvement amendment (CLIA) waiver designations. Rob has served as a consultant and/or acted on the advisory Board of a number of medical companies, including Allergen Inc., NovaBay Pharmaceuticals and Actin BioMed. Rob currently acts as an advisor for Quidel Corporation, a U.S. based manufacturer of diagnostic healthcare products.
|Mr Samuel Ross Garland Lanyon||Executive Chairman,Executive Director||Dec 2018||
Mr Samuel Ross Garland Lanyon
Executive Chairman,Executive Director
Mr Lanyon has over 25 years' experience in business strategy, R&D and operational roles in the healthcare and technology markets. Sam co-founded and serves as co-CEO of Planet Innovation, a technology and commercialization company focused on global health-tech markets. Planet Innovation has assisted in the development/ creation of four standalone businesses (Lumos Diagnostics, Visus Therapeutics, Zen Ecosystems and Atomo Biosciences) since 2015. Sam previously served as an executive at ASX listed Vision Systems, where he was responsible for establishing and growing international commercial operations for its Vision Systems division until its acquisition by Danaher Corporation in 2007. Sam currently serves on the boards of Visus Therapeutics, Planet Innovation and Paragon Funds, and previously served on the boards of Zen Ecosystems and Waterwerx. He has undertaken governance training from the Australian Institute of Company Directors (AICD).
|Ms Melanie Jaye Leydin||Chief Financial Officer,Company Secretary||N/A|
|Ms Tracy Weimar||Company Secretary||N/A|
LDX directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|28/10/21||Samuel Lanyon||Issued||120,000||$1.25||$150,000||Issue of securities|
|28/10/21||Robert Sambursky||Issued||24,000||$1.25||$30,000||Issue of securities|
The current holdings of LDX directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Bronwyn Le Grice||01/11/2020||N/A||28,400||N/A||N/A|
No Substantial Shareholders for LDX in our database.
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|16-09-21||Perennial Value Management Limited||1,614,847||9.14||10.21|
|30-07-21||Perennial Value Management Limited||1,988,790||7.81||9.14|
|06-07-21||Acorn Capital Limited||8,973,877||--||5.98|
|05-07-21||Ellerston Capital Limited||8,155,980||--||5.43|
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.